Schizophrenia Clinical Trials in Stanford, California

4 studies are recruiting for schizophrenia in Stanford, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Brenipatide in Adult Participants With Schizophrenia

    The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

    Stage
    Phase 2
    Ages
    18 to 55
    Site
    Stanford University School of Medicine, Stanford, California
    Locations
    103 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07410507 on ClinicalTrials.gov

  2. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

    Stage
    Not phased
    Ages
    18 and older
    Site
    Local Institution - 0028, Stanford, California
    Locations
    55 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07379827 on ClinicalTrials.gov

  3. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

    To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

    Stage
    Phase 3
    Ages
    10 to 17
    Site
    Alkermes Investigator Site, Stanford, California
    Locations
    47 in total
    Run by
    Alkermes, Inc.

    See if you can join NCT05303064 on ClinicalTrials.gov

  4. Imaging Synapses With [11C] UCB-J in the Human Brain

    The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented abi…

    Stage
    Phase 1
    Ages
    18 to 65
    Site
    Stanford University, Stanford, California
    Locations
    2 in total
    Run by
    Davidzon, Guido, M.D.

    See if you can join NCT04038840 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.